Research programme: selective nicotinic acetylcholine receptor antagonists - Suven Life Sciences

Drug Profile

Research programme: selective nicotinic acetylcholine receptor antagonists - Suven Life Sciences

Latest Information Update: 05 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Suven Life Sciences
  • Class
  • Mechanism of Action Alpha4beta2 nicotinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Major depressive disorder

Highest Development Phases

  • Preclinical Pain

Most Recent Events

  • 29 Jun 2016 Suven Life Sciences has patent protection for selective alpha-4-beta-2 receptor antagonists in Eurasia
  • 13 Jul 2015 Suven Life Sciences has patent protection for selective alpha-4-beta-2 nicotinic receptor antagonists in Mexico
  • 22 May 2015 Suven Life Sciences has patent protection for selective alpha-4-beta-2 nicotinic receptor antagonists in Mexico and Singapore
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top